Atomwise develops machine learning-based discovery engines and uses artificial intelligence (AI)--based neural networks to help discover new medicines. It predicts drug candidates for pharmaceutical companies, start-ups, and research institutions and designs drugs using computational drug design. It was formerly known as Chematria. The company was founded in 2012 and is based in San Francisco, California.

Healx is a technology company focused on artificial intelligence (AI) drug discovery for rare disease treatment within the pharmaceutical industry. The company specializes in using AI to identify drug-disease relationships and accelerate the development of new therapies for rare conditions. Healx's approach aims to increase the scale and success rate of rare disease treatment development by repurposing known compounds and running multiple drug discovery programs in parallel. Healx was formerly known as Healx3. It was founded in 2014 and is based in Cambridge, United Kingdom.

Aria Pharmaceuticals operates as a preclinical-stage pharmaceutical company that focuses on the discovery and development of novel, small-molecule therapies in the pharmaceutical industry. The company's main service is the development of new treatments for complex and hard-to-treat diseases using its proprietary symphony platform, which combines biomedical data and artificial intelligence to increase the success rates of drug discovery. Aria Pharmaceuticals primarily serves the healthcare sector, specifically targeting areas where new therapies are most needed. It was founded in 2014 and is based in Palo Alto, California.

Standigm is an AI-driven drug discovery company operating in the pharmaceutical industry. The company's main services include the use of proprietary AI platforms for novel target identification, lead generation, and the creation of commercially valuable drug pipelines. Standigm primarily sells to the pharmaceutical and healthcare industries. It was founded in 2015 and is based in Seoul, South Korea.

Aitia focuses on the development and application of Causal AI and Digital Twins in the pharmaceutical industry. The company's main services include the discovery of drugs for neurodegenerative disorders, oncology, and immunology by revealing hidden biological mechanisms of diseases and creating Digital Twins. It is used to discover novel therapies and accelerate research and development in various diseases such as Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, multiple myeloma, prostate cancer, and pancreatic cancer. It was founded in 2000 and is based in Cambridge, Massachusetts.

Insilico Medicine offers biotechnology software operating in pharmaceutical research and development. It offers services such as novel target discovery, generation of molecular structures with desired properties, and clinical trial analysis. Its services primarily cater to the healthcare industry, with a particular emphasis on the discovery and development of innovative drugs for a range of conditions, including cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. It was founded in 2014 and is based in Hong Kong.